Drug Information Association Logo
Corporate Tagline

Current Region: Global

About the EuroMeeting Press & Media
I am interested in...

[Close]

Help

Your selections will be saved and used to recommend products based on your interests.

Advanced Search

Search Programme

Bookmark Print

Search Program 

Title Event Type Day Time Track(s) Credits
MAKING THE MOST OUT OF THE DIA EUROMEETING IN ORDER TO ENTER THE INDUSTRY SESSION Monday, Mar 04 9:00AM - 10:30AM Theme 18 - Stand-Alone Sessions
Tutorial 01: Highlights on the Implementation of the New Pharmacovigilance Legislation with regards to Adverse Reaction Reporting Rules, Use of New International Standards and Signal Management in Eudravigilance TUTORIAL Monday, Mar 04 9:00AM - 12:30PM Tutorials - Pre-conference tutorials
Tutorial 02: Analysis of Safety Data from Clinical Trials TUTORIAL Monday, Mar 04 9:00AM - 12:30PM Tutorials - Pre-conference tutorials
Tutorial 03: Update on Practical Work with Variation Regulation TUTORIAL Monday, Mar 04 9:00AM - 12:30PM Tutorials - Pre-conference tutorials
Tutorial 04: Introduction to Medical Device Regulation TUTORIAL Monday, Mar 04 9:00AM - 12:30PM Tutorials - Pre-conference tutorials
Tutorial 05: Recent and Current developments in Pharmaceutical Law TUTORIAL Monday, Mar 04 9:00AM - 12:30PM Tutorials - Pre-conference tutorials
Tutorial 07: The Dialogue and Negotiation Process Between Applying Company and the Paediatric Committeeof the European Medicnies Agency TUTORIAL Monday, Mar 04 9:00AM - 12:30PM Tutorials - Pre-conference tutorials
Tutorial 08: Health Technology Assessment of Drugs and Medical Devices TUTORIAL Monday, Mar 04 9:00AM - 12:30PM Tutorials - Pre-conference tutorials
Tutorial 09: The European QP for Pharmacovigilance: Everything you ever Wanted to know but were afraid to ask TUTORIAL Monday, Mar 04 9:00AM - 12:30PM Tutorials - Pre-conference tutorials
Tutorial 10: Non-Clinical Safety Assessment in Global Pharmaceutical Development TUTORIAL Monday, Mar 04 9:00AM - 12:30PM Tutorials - Pre-conference tutorials
Tutorial 11: Interactions between Regulatory and Intellectual Property, Privacy and Product Liability TUTORIAL Monday, Mar 04 9:00AM - 12:30PM Tutorials - Pre-conference tutorials
Tutorial 12: Development Safety Update Report (DSUR) Kick-off in 2011: Then and Know TUTORIAL Monday, Mar 04 9:00AM - 12:30PM Tutorials - Pre-conference tutorials
Tutorial 13: Technology Transfer for Biopharmaceuticals Workshop TUTORIAL Monday, Mar 04 9:00AM - 12:30PM Tutorials - Pre-conference tutorials
Tutorial 14: Pharmacovigilance Audits and Inspections TUTORIAL Monday, Mar 04 9:00AM - 12:30PM Tutorials - Pre-conference tutorials
Tutorial 15: Coding with Confidence TUTORIAL Monday, Mar 04 9:00AM - 12:30PM Tutorials - Pre-conference tutorials
Tutorial 16: Understanding Translational Medicine: Benefits and Innovative Approaches TUTORIAL Monday, Mar 04 9:00AM - 12:30PM Tutorials - Pre-conference tutorials
Tutorial 17: Creating Compliant Clinical Study Reports for the EU and US TUTORIAL Monday, Mar 04 9:00AM - 12:30PM Tutorials - Pre-conference tutorials
Roundtable 01: GCP Inspections and Audit Findings TUTORIAL Monday, Mar 04 9:00AM - 12:30PM Tutorials - Pre-conference tutorials
YOUNG PROFESSIONALS IN THE PHARMACEUTICAL INDUSTRY SESSION Monday, Mar 04 11:00AM - 12:30PM Theme 18 - Stand-Alone Sessions
ENHANCING YOUR SOFT SKILLS BY IMPROVING YOUR EMOTIONAL INTELLIGENCE (EQ) SESSION Monday, Mar 04 11:00AM - 12:30PM Theme 18 - Stand-Alone Sessions
Opening Plenary: Public/Private Partnerships: Working together in the interest of patients SESSION Monday, Mar 04 3:40PM - 5:15PM Theme 18 - Stand-Alone Sessions
MECHANISM OF ACTION - THE LEADING PARADIGM SESSION Tuesday, Mar 05 9:00AM - 10:30AM Theme 02 - Development of Medicinal Products for Paediatric, Elderly and other
REGULATORY DATA PROTECTION SESSION Tuesday, Mar 05 9:00AM - 10:30AM Theme 03 - Legal/Transparency-Risk Assessment
IMPLEMENTATION OF THE NEW PHARMACOVIGILANCE LEGISLATION SESSION Tuesday, Mar 05 9:00AM - 10:30AM Theme 04 - Pharmacovigilance
NEW APPROACHES FOR MONITORING SESSION Tuesday, Mar 05 9:00AM - 10:30AM Theme 05 - Clinical Research and Development
DRUG SHORTAGE MANAGEMENT- ENSURING MEDICINE SUPPLY SESSION Tuesday, Mar 05 9:00AM - 10:30AM Theme 06 - Quality (including Falsified Medicines)
CURRENT STATUS OF REVISION OF EU MEDICAL DEVICE DIRECTIVES: THE KEY THEMES AND CONTROVERSIES SESSION Tuesday, Mar 05 9:00AM - 10:30AM Theme 07 - Devices & In Vitro Diagnostics and Drug/Device Combination Products
MIGRATION FROM PAPER TO ELECTRONIC SESSION Tuesday, Mar 05 9:00AM - 10:30AM Theme 08 - eTools and Data Management
LEARNED SOCIETIES AND DRUG REGULATION SESSION Tuesday, Mar 05 9:00AM - 10:30AM Theme 09 - Involvement of Patients and Academia as Experts in the Drug Approval Process
NEW RULES FOR ASSESSMENT OF KNOWN ACTIVE SUBSTANCES SESSION Tuesday, Mar 05 9:00AM - 10:30AM Theme 10 - Known Active Substances
BOTTLENECKS IN RESEARCH: HOW DO WE REPLENISH THE PIPELINE? SESSION Tuesday, Mar 05 9:00AM - 10:30AM Theme 11 - Effective Antibacterials: The present and the future
THE EU DRUG DEVELOPMENT AND APPROVAL SYSTEM: ADAPTING THE FRAMEWORK OF DRUG DEVELOPMENT AND APPROVALS TO ENABLE R&D INNOVATION AND SUPPORT SOCIETAL NEEDS - AN OUTLOOK ON THE CHANGING ENVIRONMENT FOR 2020 SESSION Tuesday, Mar 05 9:00AM - 10:30AM Theme 12 - Effectiveness and Efficiency in the EU Regulatory system - Does new legislation work?
SAFE, EFFECTIVE AND AFFORDABLE MEDICINAL PRODUCTS FOR A GLOBAL POPULATION SESSION Tuesday, Mar 05 9:00AM - 10:30AM Theme 13 - Globalisation
SETTING THE SCENE: IMPORTANCE OF REGULATORY SCIENCE THROUGHOUT SESSION Tuesday, Mar 05 9:00AM - 10:30AM Theme 14 - Regulatory Science
PUBLIC PRIVATE PARTNERSHIP FOR BIOMEDICAL RESEARCH UNDER HORIZON 2020: PATIENTS’ PERSPECTIVE ON SCIENTIFIC PRIORITIES SESSION Tuesday, Mar 05 9:00AM - 10:30AM Theme 18 - Stand-Alone Sessions
THE EUROPEAN LANDSCAPE ON HTA - THE EUnetHTA JOINT ACTION SESSION Tuesday, Mar 05 11:00AM - 12:30PM Theme 01 - HTA/Sustainability of Health Systems in Europe
COHORT STUDIES OF THE ELDERLY AS A TOOL FOR DRUG DEVELOPMENT AND TESTING SESSION Tuesday, Mar 05 11:00AM - 12:30PM Theme 02 - Development of Medicinal Products for Paediatric, Elderly and other
INCENTIVES FOR PAEDIATRIC CLINICAL RESEARCH SESSION Tuesday, Mar 05 11:00AM - 12:30PM Theme 03 - Legal/Transparency-Risk Assessment
BENEFIT/RISK MANAGEMENT IN PHARMACOVIGILANCE SESSION Tuesday, Mar 05 11:00AM - 12:30PM Theme 04 - Pharmacovigilance
BEST PRACTICES IN PHARMACOVIGILANCE GOVERNANCE SESSION Tuesday, Mar 05 11:00AM - 12:30PM Theme 04 - Pharmacovigilance
WHY TRIALS FAIL AND HOW TO PREVENT THIS SESSION Tuesday, Mar 05 11:00AM - 12:30PM Theme 05 - Clinical Research and Development
THE EU QUALIFIED PERSON IN A GLOBAL ENVIRONMENT SESSION Tuesday, Mar 05 11:00AM - 12:30PM Theme 06 - Quality (including Falsified Medicines)
DEVELOPMENT AND REGULATORY FRAMEWORK FOR COMPANION DIAGNOSTICS SESSION Tuesday, Mar 05 11:00AM - 12:30PM Theme 07 - Devices & In Vitro Diagnostics and Drug/Device Combination Products
CLINICAL STANDARDS AND METADATA SESSION Tuesday, Mar 05 11:00AM - 12:30PM Theme 08 - eTools and Data Management
PATIENTS AS EXPERTS IN DRUG REGULATION SESSION Tuesday, Mar 05 11:00AM - 12:30PM Theme 09 - Involvement of Patients and Academia as Experts in the Drug Approval Process
HARMONISATION: CHALLENGES IN PRODUCT INFORMATION / LABELLING SESSION Tuesday, Mar 05 11:00AM - 12:30PM Theme 10 - Known Active Substances
PRAGMATIC REGULATION - ROLE OF GUIDELINES IN STIMULATING DEVELOPMENT OF NEW ANTIBIOTICS SESSION Tuesday, Mar 05 11:00AM - 12:30PM Theme 11 - Effective Antibacterials: The present and the future
INTERNATIONAL COLLABORATION IN THE REVIEW OF GENERIC DRUGS SESSION Tuesday, Mar 05 11:00AM - 12:30PM Theme 13 - Globalisation
THE WAY FORWARD IN CNS: REGULATORY SCIENCE AT THE EDGE SESSION Tuesday, Mar 05 11:00AM - 12:30PM Theme 14 - Regulatory Science
COMPARATIVE EFFECTIVENESS AS PART OF THE PUBLIC ASSESSMENT REPORT (PAR) SESSION Tuesday, Mar 05 2:00PM - 3:30PM Theme 01 - HTA/Sustainability of Health Systems in Europe
COMPARATIVE EFFECTIVENESS AS PART OF THE PUBLIC ASSESSMENT REPORT (PAR) SESSION Tuesday, Mar 05 2:00PM - 3:30PM Theme 01 - HTA/Sustainability of Health Systems in Europe
CANCELLED: DEVELOPMENT OF INNOVATIVE INTERVENTIONS FOR HEALTHY AGEING: HOW FAR DID WE GET? SESSION Tuesday, Mar 05 2:00PM - 3:30PM Theme 02 - Development of Medicinal Products for Paediatric, Elderly and other
LEGAL COMPLIANCE FOR REGULATORY FUNCTIONS - LEARNINGS FROM RECENT ENFORCEMENT ACTIVITIES SESSION Tuesday, Mar 05 2:00PM - 3:30PM Theme 03 - Legal/Transparency-Risk Assessment
ENHANCING CLINICAL RESEARCH EFFECTIVENESS SESSION Tuesday, Mar 05 2:00PM - 3:30PM Theme 05 - Clinical Research and Development
FALSIFIED MEDICINES DIRECTIVE AND ACTIVE SUBSTANCES SESSION Tuesday, Mar 05 2:00PM - 3:30PM Theme 06 - Quality (including Falsified Medicines)
CHANGES IN EU APPROVAL OF DRUG/DEVICE COMBINATIONS – THE NEW REGULATORY STRUCTURE AND HOW IT WILL IMPACT INNOVATION SESSION Tuesday, Mar 05 2:00PM - 3:30PM Theme 07 - Devices & In Vitro Diagnostics and Drug/Device Combination Products
PHARMACOVIGILANCE AND MEDICINAL PRODUCT STANDARDS AND METADATA SESSION Tuesday, Mar 05 2:00PM - 3:30PM Theme 08 - eTools and Data Management
MAINTENANCE OF MEDICINAL PRODUCTS WITH KNOWN ACTIVE SUBSTANCES – VARIATIONS SESSION Tuesday, Mar 05 2:00PM - 3:30PM Theme 10 - Known Active Substances
PRESERVING WHAT WE HAVE - PRUDENT AND CONTROLLED USE SESSION Tuesday, Mar 05 2:00PM - 3:30PM Theme 11 - Effective Antibacterials: The present and the future
FIRST EXPERIENCE WITH THE PHARMACOVIGILANCE LEGISLATION SESSION Tuesday, Mar 05 2:00PM - 3:30PM Theme 12 - Effectiveness and Efficiency in the EU Regulatory system - Does new legislation work?
SFDA SESSION - GMP IN CHINA SESSION Tuesday, Mar 05 2:00PM - 3:30PM Theme 13 - Globalisation
THE ESCHER PROJECT: REGULATORY SCIENCE IN PRACTICE SESSION Tuesday, Mar 05 2:00PM - 3:30PM Theme 14 - Regulatory Science
ELECTRONIC HEALTH RECORDS SESSION Tuesday, Mar 05 2:00PM - 3:30PM Theme 18 - Stand-Alone Sessions
CANCELLED: HTA AND PRICING POLICIES IN EU AFTER THE TRANSPARENCY DIRECTIVE SESSION Tuesday, Mar 05 4:00PM - 5:30PM Theme 01 - HTA/Sustainability of Health Systems in Europe
BIOSIMILARS SESSION Tuesday, Mar 05 4:00PM - 5:30PM Theme 03 - Legal/Transparency-Risk Assessment
ADAPTIVE CLINICAL TRIAL DESIGNS SESSION Tuesday, Mar 05 4:00PM - 5:30PM Theme 05 - Clinical Research and Development
FALSIFIED MEDICINES DIRECTIVE AND SERIALISATION SESSION Tuesday, Mar 05 4:00PM - 5:30PM Theme 06 - Quality (including Falsified Medicines)
HOW TO ADDRESS DIFFERENT REQUIREMENTS DEVELOPING COMBINATION PRODUCTS: THE CHALLENGES OF MANAGING TWO SETS OF RULES SESSION Tuesday, Mar 05 4:00PM - 5:30PM Theme 07 - Devices & In Vitro Diagnostics and Drug/Device Combination Products
MESSAGES FROM THE AGENCIES SESSION Tuesday, Mar 05 4:00PM - 5:30PM Theme 08 - eTools and Data Management
HANDLING CONFLICT OF INTEREST (COI) SESSION Tuesday, Mar 05 4:00PM - 5:30PM Theme 09 - Involvement of Patients and Academia as Experts in the Drug Approval Process
XEVMPD: LONG-TERM EXPECTATIONS AND BENEFITS SESSION Tuesday, Mar 05 4:00PM - 5:30PM Theme 10 - Known Active Substances
NEW APPROACHES TO COMBAT RESISTANCE SESSION Tuesday, Mar 05 4:00PM - 5:30PM Theme 11 - Effective Antibacterials: The present and the future
EARLY DIALOGUE IN DRUG DEVELOPMENT SESSION Tuesday, Mar 05 4:00PM - 5:30PM Theme 12 - Effectiveness and Efficiency in the EU Regulatory system - Does new legislation work?
PATIENT AND CONSUMER ROLES: THEIR INPUT IN REGULATORY SCIENCE SESSION Tuesday, Mar 05 4:00PM - 5:30PM Theme 14 - Regulatory Science
GCP HOT TOPICS: THE CHALLENGES IN THE CRO-SPONSOR RELATIONSHIP SESSION Tuesday, Mar 05 4:00PM - 5:30PM Theme 18 - Stand-Alone Sessions
PHARMACEUTICAL LAW IN THE NETHERLANDS: BUILDING AN EU ASSOCIATION? SESSION Tuesday, Mar 05 6:00PM - 7:30PM Theme 18 - Stand-Alone Sessions
FOCUS ON MANAGED ENTRY AGREEMENTS (AND REAL WORLD DATA) SESSION Wednesday, Mar 06 9:00AM - 10:30AM Theme 01 - HTA/Sustainability of Health Systems in Europe
HOW TO OPTIMISE CLINICAL DEVELOPMENT IN THE ELDERLY: SOME PRACTICAL EXAMPLES SESSION Wednesday, Mar 06 9:00AM - 10:30AM Theme 02 - Development of Medicinal Products for Paediatric, Elderly and other
FROM VOLUNTARY HARMONISATION TO CLINICAL TRIAL REGULATION L TRIALS SESSION Wednesday, Mar 06 9:00AM - 10:30AM Theme 03 - Legal/Transparency-Risk Assessment
NEW OPPORTUNITIES FOR INFORMATION TECHNOLOGY IN PHARMACOVIGILANCE SESSION Wednesday, Mar 06 9:00AM - 10:30AM Theme 04 - Pharmacovigilance
QUALITY UPDATE - CURRENT DEVELOPMENTS SESSION Wednesday, Mar 06 9:00AM - 10:30AM Theme 06 - Quality (including Falsified Medicines)
LATEST US REGULATORY MOVES TOWARDS FOSTERING INNOVATION: UPDATE ON MAIN NEW AND REVISED REGULATIONS AND GUIDANCE SESSION Wednesday, Mar 06 9:00AM - 10:30AM Theme 07 - Devices & In Vitro Diagnostics and Drug/Device Combination Products
SOCIAL MEDIA/USE OF TABLETS AND SMARTPHONES SESSION Wednesday, Mar 06 9:00AM - 10:30AM Theme 08 - eTools and Data Management
KNOWN ACTIVE SUBSTANCES FOR THE SELF-CARE SECTOR SESSION Wednesday, Mar 06 9:00AM - 10:30AM Theme 10 - Known Active Substances
INNOVATIVE APPROACHES TO PRODUCT INFORMATION FOR PHYSICIANS AND PATIENTS SESSION Wednesday, Mar 06 9:00AM - 10:30AM Theme 12 - Effectiveness and Efficiency in the EU Regulatory system - Does new legislation work?
MNC’S EXPANSION IN EMERGING MARKETS: OPPORTUNITIES AND CHALLENGES SESSION Wednesday, Mar 06 9:00AM - 10:30AM Theme 13 - Globalisation
A CASE STUDY USING THE FRAMEWORK SUPPORTED BY QUANTATATIVE METHODS FOR BENEFIT/RISK ASSESSMENT SESSION Wednesday, Mar 06 9:00AM - 10:30AM Theme 15 - Growing Demand for Quantitative Approaches in Drug Development
NON-CLINICAL TESTING FOR ADVANCED THERAPY SESSION Wednesday, Mar 06 9:00AM - 10:30AM Theme 16 - Non-Clinical
FOCUS ON MEDICINES EFFICACY, SAFETY AND USAGE IN EDUCATION AND TRAINING SESSION Wednesday, Mar 06 9:00AM - 10:30AM Theme 17 - IMI Public-Private Partnership in Medicines Research Education and Training – for Professionals and for Patients
EMA ROUNDTABLE- SCIENTIFIC COMMITTEES UNITED IN DIVERSITY SESSION Wednesday, Mar 06 9:00AM - 10:30AM Theme 18 - Stand-Alone Sessions
THE IMPACT OF THE NEW PHARMACOVIGILANCE LEGISLATION INSTRUMENTS ON HTAS SESSION Wednesday, Mar 06 11:00AM - 12:30PM Theme 01 - HTA/Sustainability of Health Systems in Europe
PAEDIATRIC CLINICAL TRIALS – TRIAL BY DESIGN SESSION Wednesday, Mar 06 11:00AM - 12:30PM Theme 02 - Development of Medicinal Products for Paediatric, Elderly and other
TRANSPARENCY ON DOSSIER AND DECISION MAKING – HAS PUBLIC TRUST INCREASED? SESSION Wednesday, Mar 06 11:00AM - 12:30PM Theme 03 - Legal/Transparency-Risk Assessment
RISK COMMUNICATION AND TRANSPARENCY SESSION Wednesday, Mar 06 11:00AM - 12:30PM Theme 04 - Pharmacovigilance
ADOPTION OF GAME CHANGING TECHNOLOGIES SESSION Wednesday, Mar 06 11:00AM - 12:30PM Theme 05 - Clinical Research and Development
INTERNATIONAL HARMONISATION: GLOBAL REGULATORS’ PROGRESS FROM GHTF TO IMDRF - ARE WE ANY NEARER TO REGULATORY CONVERGENCE? SESSION Wednesday, Mar 06 11:00AM - 12:30PM Theme 07 - Devices & In Vitro Diagnostics and Drug/Device Combination Products
ATTRIBUTING SAFETY REPORTS TO MEDICINAL PRODUCTS SESSION Wednesday, Mar 06 11:00AM - 12:30PM Theme 08 - eTools and Data Management
BIOSIMILARS: DEVELOPING A MORE THOROUGH UNDERSTANDING OF A KNOWN ACTIVE SUBSTANCE SESSION Wednesday, Mar 06 11:00AM - 12:30PM Theme 10 - Known Active Substances
ENVIRONMENTAL CONSIDERATIONS IN PRODUCTION OF MEDICINAL PRODUCTS SESSION Wednesday, Mar 06 11:00AM - 12:30PM Theme 13 - Globalisation
EQUIVALENCE OF ORALLY INHALED PRODUCTS SESSION Wednesday, Mar 06 11:00AM - 12:30PM Theme 15 - Growing Demand for Quantitative Approaches in Drug Development
NEW TRENDS IN INVITRO NON-CLINICAL TESTING SESSION Wednesday, Mar 06 11:00AM - 12:30PM Theme 16 - Non-Clinical
QUALITY CAREER DEVELOPMENT IN GLOBAL MEDICINES DEVELOPMENT SESSION Wednesday, Mar 06 11:00AM - 12:30PM Theme 17 - IMI Public-Private Partnership in Medicines Research Education and Training – for Professionals and for Patients
JAPANESE REGULATORY SESSION – PMDA UPDATE SESSION Wednesday, Mar 06 11:00AM - 12:30PM Theme 18 - Stand-Alone Sessions
QUALITY RISK MANAGEMENT WORKSHOP WORKSHOP Wednesday, Mar 06 11:00AM - 12:30PM Theme 18 - Stand-Alone Sessions
THE PATIENTS’ PERSPECTIVE ON HTA SESSION Wednesday, Mar 06 2:00PM - 3:30PM Theme 01 - HTA/Sustainability of Health Systems in Europe
LEGAL AND PRACTICAL ASPECTS OF OFF-LABEL USE SESSION Wednesday, Mar 06 2:00PM - 3:30PM Theme 03 - Legal/Transparency-Risk Assessment
IMPACT OF ICH E2C (R2) AND GVP MODULE VII SESSION Wednesday, Mar 06 2:00PM - 3:30PM Theme 04 - Pharmacovigilance
PATIENT RECRUITMENT AND RETENTION SESSION Wednesday, Mar 06 2:00PM - 3:30PM Theme 05 - Clinical Research and Development
PHARMACOPOEIAL HARMONISATION- A NEVER ENDING STORY SESSION Wednesday, Mar 06 2:00PM - 3:30PM Theme 06 - Quality (including Falsified Medicines)
HOW SYNERGY BETWEEN DATA MANAGEMENT AND TECHNOLOGY WILL DRIVE CLINICAL DEVELOPMENT IN THE NEXT DECADE SESSION Wednesday, Mar 06 2:00PM - 3:30PM Theme 08 - eTools and Data Management
COMBINATION MEDICINAL DRUG PRODUCTS OF KNOWN ACTIVE SUBSTANCES SESSION Wednesday, Mar 06 2:00PM - 3:30PM Theme 10 - Known Active Substances
REGULATORY TOWN HALL MEETING SESSION Wednesday, Mar 06 2:00PM - 3:30PM Theme 12 - Effectiveness and Efficiency in the EU Regulatory system - Does new legislation work?
ASIAN STRATEGY OF THE USA, EUROPE AND JAPAN SESSION Wednesday, Mar 06 2:00PM - 3:30PM Theme 13 - Globalisation
SUBGROUP ANALYSES SESSION Wednesday, Mar 06 2:00PM - 3:30PM Theme 15 - Growing Demand for Quantitative Approaches in Drug Development
NEW ICH INITIATIVES IN SAFETY TESTING SESSION Wednesday, Mar 06 2:00PM - 3:30PM Theme 16 - Non-Clinical
EUPATI - THE EUROPEAN PATIENTS ACADEMY ON THERAPEUTIC INNOVATION – AN UNPRECEDENTED PUBLIC PRIVATE PARTNERSHIP TO EMPOWER PATIENTS TO ENGAGE AS REAL PARTNERS IN THE DRUG DEVELOPMENT PROCESS SESSION Wednesday, Mar 06 2:00PM - 3:30PM Theme 17 - IMI Public-Private Partnership in Medicines Research Education and Training – for Professionals and for Patients
PERSPECTIVES AND COLLABORATION BETWEEN PATIENTS AND STUDENTS SESSION Wednesday, Mar 06 2:00PM - 3:30PM Theme 18 - Stand-Alone Sessions
HTA AND OFF-LABEL USE SESSION Wednesday, Mar 06 4:00PM - 5:30PM Theme 01 - HTA/Sustainability of Health Systems in Europe
PAEDIATRIC REQUIREMENTS – DO THEY DELIVER AND AT WHICH COST? SESSION Wednesday, Mar 06 4:00PM - 5:30PM Theme 02 - Development of Medicinal Products for Paediatric, Elderly and other
DEVELOPMENT OF PHARMACOVIGILANCE METHODOLOGY SESSION Wednesday, Mar 06 4:00PM - 5:30PM Theme 04 - Pharmacovigilance
COLLECTING RELEVANT HEALTH OUTCOME DATA SESSION Wednesday, Mar 06 4:00PM - 5:30PM Theme 05 - Clinical Research and Development
HARMONISATION – PITFALLS AND HOW CAN WE SPEED IT UP? SESSION Wednesday, Mar 06 4:00PM - 5:30PM Theme 06 - Quality (including Falsified Medicines)
WHICH EU REGULATORY RULES FOR TELEMEDICINE, EHEALTH AND MHEALTH? HOW CAN INNOVATION BE ENCOURAGED? SESSION Wednesday, Mar 06 4:00PM - 5:30PM Theme 07 - Devices & In Vitro Diagnostics and Drug/Device Combination Products
CLINICAL TRIALS IN EUROPE: WILL THE REVISED LEGISLATION MEET THE DEMANDS OF TOMORROW? SESSION Wednesday, Mar 06 4:00PM - 5:30PM Theme 12 - Effectiveness and Efficiency in the EU Regulatory system - Does new legislation work?
STATISTICAL HOT TOPICS IN SCIENTIFIC ADVICE SESSION Wednesday, Mar 06 4:00PM - 5:30PM Theme 15 - Growing Demand for Quantitative Approaches in Drug Development
OVERVIEW OF CURRENT DISCUSSIONS IN ICH SESSION Wednesday, Mar 06 4:00PM - 5:30PM Theme 16 - Non-Clinical
TOWARDS A EUROPEAN FRAMEWORK FOR CONTINUING PROFESSIONAL DEVELOPMENT IN A LIFE-LONG LEARNING PERSPECTIVE SESSION Wednesday, Mar 06 4:00PM - 5:30PM Theme 17 - IMI Public-Private Partnership in Medicines Research Education and Training – for Professionals and for Patients
Contact Us Home Legal Site Map
© 2013 DIA